Post transplant outcomes in patients with Hodgkin lymphoma following autologous stem cell transplantation mobilised with Plerixafor

Trial Profile

Post transplant outcomes in patients with Hodgkin lymphoma following autologous stem cell transplantation mobilised with Plerixafor

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Plerixafor (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2017 New trial record
    • 01 Sep 2017 Results published in the Hematological Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top